Compare AGBK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AGBK | ANL |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 998.8M |
| IPO Year | 2025 | 2022 |
| Metric | AGBK | ANL |
|---|---|---|
| Price | $5.88 | $15.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $17.20 | ★ $20.00 |
| AVG Volume (30 Days) | 155.2K | ★ 156.7K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $235.22 | N/A |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.73 | $0.88 |
| 52 Week High | $12.21 | $17.25 |
| Indicator | AGBK | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 55.70 |
| Support Level | N/A | $12.07 |
| Resistance Level | $7.42 | $17.25 |
| Average True Range (ATR) | 0.21 | 1.11 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 10.14 | 45.26 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.